Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers

Clinical and Translational Science

Volumn 9, Issue 3, 2016, Pages 176-180

  Nagalla, S ^a   Thomson, L ^b   Oppong, Y ^a   Bachman, B ^a   Chervoneva, I ^a   Kraft, W K ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A; PROTHROMBIN COMPLEX;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBIN TIME; THROMBOCYTE COUNT; UNSPECIFIED SIDE EFFECT;

EID: 84975045700     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12398     Document Type: Article

References (16)

1. Hirsh, J. et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119 (1 Suppl), 8S–21S (2001).
2. Holbrook, A. et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2 Suppl), e152S–e184S (2012).
3. Baumann Kreuziger, L.M., Morton, C.T. & Dries, D.J. New anticoagulants: a concise review. J. Trauma Acute Care Surg. 73, 983–992 (2012).
4. Tahir, F. et al. The new oral anti-coagulants and the phase 3 clinical trials – a systematic review of the literature. Thromb. J. 11, 18 (2013).
5. Lopes, R.D. et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am. Heart J. 159, 331–339 (2010).
6. Siegal, D.M. & Cuker, A. Reversal of novel oral anticoagulants in patients with major bleeding. J. Thromb. Thrombolysis 35, 391–398 (2013).
7. Eerenberg, E.S., Kamphuisen, P.W., Sijpkens, M.K., Meijers, J.C., Buller, H.R. & Levi, M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124, 1573–1579 (2011).
8. Escolar, G. et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One 8, e78696 (2013).
9. Wong, P.C., White, A. & Luettgen, J. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. Hosp. Pract. (1995) 41, 19–25 (2013).
10. Kenward, M.G. & Roger, J.H. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 53, 983–997 (1997).
11. Cheung, Y.W., Barco, S., Hutten, B.A., Meijers, J.C., Middeldorp, S. & Coppens, M. In vivo increase of thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. J. Thromb. Haemost. 13, 1799–1805 (2015).
12. Dzik, W.H. Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisal. J. Thromb. Haemost. 13, (Suppl 1), S187–S194 (2015).
13. Herzog, E. et al. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding. Thromb. Res. 135, 554–560 (2015).
14. Martin, A.C. et al. Multimodal assessment of non-specific hemostatic agents for apixaban reversal. J. Thromb. Haemost. 13, 426–436 (2015).
15. Martin, A.C. et al. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int. J. Cardiol. 168, 4228–4233 (2013).
16. Grandhi, R. et al. Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors. World Neurosurg. 84, 1956–1961 (2015).